1 |
Branscomebe, T. L., Frankel, A., Lee, J. H., Cook, J. R., Yang, Z., Pestka, S. and Clarke, S. 2001. PRMT5 (janus kinase-binding protein 1) catalyzes the formation of symmetric dimethylarginine residues in proteins. J. Biol. Chem. 276, 32971-32976.
DOI
|
2 |
Chen, H. C. and Farese, R. V. 2005. Inhibition of triglyceride synthesis as a treatment strategy for obesity: lessons from DGAT1-deficient mice. Arterioscler. Thromb. Vasc. Biol. 25, 482-486.
DOI
|
3 |
Cooke, D. and Bloom, S. 2006. The obesity pipeline: current strategies in the development of anti-obesity drugs. Nat. Rev. Drug Discov. 5, 919-1200.
DOI
|
4 |
Fabbrizio, E., El Messaoudi, S., Polanowska, J., Paul, C., Cook, J. R., Lee, J. H., Negre, V., Rousset, M., Pestka, S., Le Cam, A. and Sardet, C. 2002. Negative regulation of transcription by the type II arginine methyltransferase PRMT5. EMBO Rep. 3, 641-645.
DOI
|
5 |
Goyal, A., Chavez, S. L. and Reijo Pera, R. A. 2013. Generation of human induced pluripotent stem cells using epigenetic regulators reveals a germ cell-like identity in partially reprogrammed colonies. PLoS One 8, e82838.
DOI
|
6 |
Gu, Z., Gao, S., Zhang, F., Wan,g Z., Ma, W. and Davis, R. E. 2012. Protein arginine methyltransferase 5 is essential for growth of lung cancer cells. Biochem. J. 446, 235-241.
DOI
|
7 |
Jang, M. J., Park, U. H., Kim, J. W., Choi, H., Um, S. J. and Kim, E. J. 2017. CACUL1 reciprocally regulates SIRT1 and LSD1 to repress PPAR and inhibit adipogenesis. Cell Death Dis. 8, 3201.
DOI
|
8 |
Liu, F., Cheng, G., Hamard, P. J., Greenblatt, S., Wang, L., Man, N., Perna, F., Xu, H., Tadi, M., Luciani, L. and Nimer, S. D. 2015. Arginine methyltransferase PRMT5 is essential for sustaining normal adult hematopoiesis. J. Clin. Invest. 125, 3532-3544.
DOI
|
9 |
Karkhanis, V., Hu, Y. J., Baiocchi, R. A., Imbalzano, A. N. and Sif, S. 2011. Versatility of PRMT5 induced methylation in growth control and development. Trends Biochem. Sci. 36, 633-641.
DOI
|
10 |
Kopelman, P. G. 2000. Obesity as a medical problem. Nature 404, 635-643.
DOI
|
11 |
Powers, M. A., Fay, M. M., Factor, R. E., Welm, A. L. and Ullman, K. S. 2011. Protein arginine methyltransferase 5 accelerates tumor growth by arginine methylation of the tumor suppressor programmed cell death 4. Cancer Res. 71, 5579-5587.
DOI
|
12 |
Rosen, E. D. and MacDougald, O. A. 2006. Adipocyte differentiation from the inside out. Nat. Rev. Mol. Cell Biol. 7, 885-896.
DOI
|
13 |
Sugii, S. and Evans, R. M. 2011. Epigenetic codes of PPARgamma in metabolic disease. FEBS Lett. 585, 2121e2128.
DOI
|
14 |
Tee, W. W., Pardo, M., Theunissen, T. W., Yu, L., Choudhary, J. S., Hajkova, P. and Surani, M. A. 2010. Prmt5 is essential for early mouse deelopment and acts in the cytoplasm to maintain ES cell pluripotency. Genes Dev. 24, 2772-2777.
DOI
|
15 |
Tontonoz, P., Hu, E. and Spiegelman, B. M. 1994. Stimulation of adipogenesis in fibroblasts by PPAR 2, a lipid-activated transcription factor. Cell 79, 1147-1156.
DOI
|
16 |
Tontonoz, P. and Spiegelman, B. M. 2008. Fat and beyond: the diverse biology of PPARgamma. Annu. Rev. Biochem. 77, 289-312.
DOI
|
17 |
Wei, T. Y., Juan, C. C., Hsia, J. Y., Su, L. J., Lee, Y. C., Chou, H. Y., Chen, J. M., Wu, Y. C., Chiu, S. C., Hsu, C. P., Liu, K. L. and Yu, C. T. 2012. PRMT5 is a potential oncoprotein that upregulates G1 cyclins/CDKs and the PI3K/AKT signaling cascade. Cancer Sci. 103, 1640-1650.
DOI
|